一些欧洲国家最近已批准临床应用红细胞生成素,明年很可能在世界范围内得到应用。重组人红细胞生成素(r-HuEPO)有165个氨基酸糖基化多肽,分子量为30 400道尔顿,主要适应症是慢性肾衰贫血(红细胞生成素缺乏者)。对贫血所依据的血红蛋白水平尚无统一标准,故应根据临床症状、对输血的依赖性和血红蛋白浓度提高后的可能风险而确定是否接受r-HuEPO 治疗。给药方式一般有静脉和皮下途径。静脉给 Some European countries have recently approved the clinical application of erythropoietin, is likely to be applied worldwide next year. Recombinant human erythropoietin (r-HuEPO) has a 165 amino acid glycosylation polypeptide, molecular weight of 30 400 daltons, the main indication is anemia of chronic renal failure (erythropoietin deficiency). There is no uniform standard for hemoglobin on which anemia is based, so r-HuEPO treatment should be based on clinical symptoms, the dependence on blood transfusion, and the possible risk of increased hemoglobin concentration. The mode of administration is generally intravenous and subcutaneous routes. Give intravenous